Is Zhengye Biotechnology Holding Ltd (ZYBT) a good stock to buy?
Two or more of our tested checks point the wrong way. When the survival check is one of them, no price makes that acceptable.
What each rating means, in numbers
Business quality — Very weak. Passes 2 of the 9 health checks we can measure — things like making a profit, turning it into cash, and not piling on debt. Across 131,000 company-quarters the weakest scorers went on to fail at 5.4% against 1.4% for the strongest, in every era and all twelve sectors.
How wild is the price? — Very wild. The share price swings about 90% in a typical year, which puts it in the most volatile fifth. Out of every 100 companies that swung like this, about 8.6 went bankrupt within the year. Across the three periods we tested that ran from 3.7% to 11.5%.
What "tested" means here, and why there is no score out of 100
Tested means the read was measured against what actually happened afterwards, on a history that keeps the companies that were later delisted, using only figures that had been filed on the day they are used. Survival was ranked on companies that really did fail. What an owner keeps was tested across the universe from 2011 to 2025.
The full record of everything we have tested is on the research pages.
Which benchmark. Over the period we tested, the median listed company returned +5.8% a year while the S&P 500 returned about +13.9% — the index is weighted by size and was carried by a handful of enormous winners. So "beats the index" and "beats the other companies you could have bought" are different questions. Where a read says it picks better companies, it means the second one. None of these gets you an index fund's return, and we would rather say that than imply otherwise.
The quality read is the strongest thing we have tested: 131,000 company-quarters across 5,300 companies, where the weakest scorers went on to fail at 5.4% against 1.4% for the strongest, holding in every era and all twelve sectors. It still says less likely to break, not likely to beat the market — every band in that study lost to the index at the median, because the median listed company does.
Each read is shown on its own rather than merged into a single score, so you can see which part is strong and which is weak instead of taking an average on trust.
▾ What goes into the smart-money reading
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend, DCF applicability). It excludes the Altman Z score, whose retained-earnings input this filer does not report separately. See the Financial Health section for the full balance-sheet read.
Chance the S&P 500 falls 10% or more in the next three months.
Counted from every day since 2006. Says nothing about ZYBT — see the board for how it is measured.
📍 Where to start on this page, and what to look at first
How to read ZYBT
ZYBT generates real cash flow, but the DCF here is a low-confidence estimate — the value is sensitive to how we normalize cash flow, cyclicality, and secular/industry risk. Treat the DCF as one input, then pressure-test it against the reverse-DCF, leverage, and the operating trends below.
-
1
The verdict + intrinsic value (our DCF) ↓
Our estimate of what a share is worth, versus today's price.
-
2
Reverse-DCF + the interactive calculator ↓
See the growth the price assumes, then flex every assumption yourself to pressure-test it.
-
3
Football field + peers ↓
A cross-check across methods and against comparable companies.
Who owns ZYBT, and how it moves
From the SEC's own filings: every fund manager over $100M reports its holdings each quarter, and every officer and director reports theirs. Each point is what was public at the time.
What growth must the market believe? Reverse DCF — Instead of asking "what is this stock worth?", asks "what growth rate is the current market price already assuming?"
Why it matters: It crystallizes the bull thesis as a single number you can argue with. If the market expects 40% growth for 10 years and you do not believe that, the stock is overvalued.
Reference: 10–15% = sustainable for strong companies · 20–25% = exceptional · 30%+ = historically very rare
Traditional DCF asks "what is this stock worth?" Reverse DCF flips it: it treats today's price as correct and solves for the growth rate that justifies it. In plain terms — if our model is right about everything else, the company's cash flow would have to grow (or shrink) by this much every year for the next 5 years for today's price to make sense. If that required growth looks unrealistic, the price is stretched; if it looks easy to beat, the price may be cheap.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → must grow at:
▾ Exactly how this 5-year figure is computed
Forecast length: 5 years at the solved rate, then a linear fade to terminal growth over years 6-10 — the same shape the DCF above uses
Terminal growth after the fade: 3.0%
Discount rate: 11.5% (the rate the model used)
Price used: $1.73 — the live price shown on this page (not frozen)
Method: solve for the constant annual growth rate that makes the discounted 10-year FCF stream + terminal value equal today's price.
Very few companies have compounded cash flow at this rate for five years. The market is pricing a near-best-case outcome.
For reference: Historically near-impossible — sustaining 30%+ cash-flow growth for a decade at scale is exceedingly rare.
▾ How we computed this · Reality check thresholds · Assumptions
- Starting FCF/share: $0.02 (TTM)
- Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation →: 11.5% — standard 8-12%; 9-10% matches S&P 500 historical return - Terminal Growth RateTerminal Growth Rate — The growth rate we assume the company holds forever, after the explicit 10-year forecast period ends.
Why it matters: It anchors the long-tail value. Cannot mathematically exceed long-term GDP growth or the company eventually becomes larger than the global economy.
Reference: 2–3% (matches long-term US GDP growth) · Above 4% is mathematically problematic
Full explanation →: 3.0% — matches long-term GDP growth - Forecast horizon: 10 years explicit + terminal perpetuity
| ≤ 0% | Priced for decline — likely undervalued OR dying business |
| 5-12% | Reasonable; sustainable for quality businesses |
| 12-18% | Demanding — strong execution required |
| 18-25% | Exceptional — few companies sustain for a decade |
| 25-35% | Heroic — historically very rare |
| 35%+ | Borderline impossible at scale |
Sustaining 30%+ cash-flow growth for a full decade at scale is exceedingly rare — the bar is brutally high.
Use the interactive calculator below to change the discount rate, growth and terminal-growth assumptions and watch the value move.
What this rating means
What the rating says — Methods disagree. Methods disagree: the price is ABOVE 2 of 3 method ranges while inside the rest — assumption-sensitive, not clearly fair.
What it does not say — Not a forecast. This shows where today's price sits against several different ways of valuing the business. Where the methods disagree, the spread itself is the useful part - it tells you how much the answer depends on which one you trust.
Football field: where does the price sit?
Different valuation methods produce different fair-value ranges depending on assumptions. Plotting them together lets you see at a glance whether the current price is reasonable across approaches, or only one specific lens.
Industry multiples sourced from: industry: Pharmaceuticals. See the Peer Basket section below for the peer comparison and its limited-comparables caveat.
How does ZYBT stack up against its closest peers?
We take the 7 same- or closely-related-industry companies closest in size to ZYBT and check what investors are paying for each dollar of their revenue (or profits). If ZYBT is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, FCF yield (in the table) is usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 7 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (8)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| SPRB | SPRUCE BIOSCIENCES, INC. | Pharmaceuticals | $142M | — | — | — | — |
| TLSA | Tiziana Life Sciences Ltd | Pharmaceuticals | $170M | — | — | — | — |
| TELO | Telomir Pharmaceuticals, Inc. | Pharmaceuticals | $89M | — | — | — | — |
| VRCA | Verrica Pharmaceuticals Inc. | Pharmaceuticals | $79M | 2.2x | — | — | 13.4% |
| TNXP | Tonix Pharmaceuticals Holding Corp | Pharmaceuticals | $197M | 15.0x | — | — | 0.6% |
| UNCY | Unicycive Therapeutics, Inc. | Pharmaceuticals | $197M | — | — | — | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Pharmaceuticals | $206M | — | — | — | — |
| XBIT | XBiotech Inc. | Pharmaceuticals ·fallback | $74M | — | — | — | — |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
What these health ratings mean, in numbers
Business quality — Very weak. Passes 2 of the 9 health checks we can measure — making a profit, turning it into cash, not piling on debt, not issuing shares. Across 131,000 company-quarters the weakest scorers went on to fail at 5.4% within a year against 1.4% for the strongest, and that held in every era and all twelve sectors. It says "less likely to break", not "likely to beat the market".
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
We can't produce a trustworthy Altman Z here: retained earnings weren't separately reported in our data, so a core input would have to be fabricated. Rather than show a categorical "distress" verdict from an invented number, we mark it unavailable. Judge financial health from the leverage, cash position, and the measurable Piotroski checks instead.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✗ Positive net incomeNet income -$10.0M in FY2025.Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
-
✓ Positive operating cash flowOperating cash flow $1.9M (was $5.6M the prior year).
-
✓ Cash flow backs up reported profitOperating cash flow $1.9M vs net income -$10.0M.
-
✗ Return on assets improvingReturn on assets -16.0% vs 2.3% a year ago.Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
-
✗ Debt load (vs assets)Long-term debt is 2.0% of assets vs 1.0% a year ago ($1.3M of $62.4M assets).Why this matters: Rising debt relative to assets means more risk and more cash going to interest instead of shareholders. Falling debt is a sign of strengthening.
-
✗ Short-term liquidity (current ratio)Current ratio 1.14x vs 1.31x a year ago.Why this matters: The current ratio compares assets it can turn to cash within a year against bills due within a year. Below 1.0 means it may struggle to cover near-term obligations.
-
✗ Share count (dilution)Share count rose 3.7% (45.7M → 47.3M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
✗ Pricing power (gross margin)Gross margin 20.5% vs 49.0% a year ago.Why this matters: Rising gross margin means stronger pricing power or lower input costs — a sign of competitive strength. Falling margin signals pressure.
-
✗ Sales per asset (asset turnover)Asset turnover 0.27x vs 0.38x a year ago.Why this matters: Asset turnover measures how much revenue each dollar of assets generates. Rising = more productive use of the asset base.
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
What if you assume different inputs?
Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 11.5%, the figure our model used for ZYBT. Open Advanced to also change beta, growth and the rate path.
Note: the calculator opens at our published value of $0.37 — it is initialised to the same scenario-weighted result, so the two match exactly on load. The moment you move a slider, the value below becomes a single-path what-if at your assumptions (not the three-scenario weighting), which is why it can differ from the headline once you've touched it.
8.5% — beta-based (CAPM), from this stock's BetaBeta — How much the stock moves when the overall market moves. 1.0 = moves with the market; 1.5 = moves 50% more than the market.
Why it matters: Higher beta = more volatile = should demand higher discount rate. Low beta stocks (utilities, consumer staples) move less.
Reference: Most stocks 0.5–1.5 · Defensives ~0.3 · High-vol tech ~1.5–2.0
Full explanation → of 0.45. The safe Treasury rate plus a premium scaled by how much more (or less) volatile the stock is than the market.
11.5% — sector/quality tier. A simpler hurdle set by industry and business durability: lower for stable, wide-moat companies; higher for speculative or micro-caps.
The headline value and this calculator start at 11.5% — the more conservative sector/quality rate (we use the more conservative sector/quality rate when model applicability is limited or the balance sheet is stretched). Drag the slider to the other rate to see the full range.
+373.3%
At the default assumptions the flat path lands near our published value of $0.37. Move any slider to recompute it with your own.
Move any slider above to recompute this against your own assumptions.
⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Zhengye Biotechnology Holding Ltd (ZYBT) is well above the model value, with the price 373.3% above intrinsic valueIntrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation → (a 373.3% premium). The market appears to be paying up for potential future growth in the pharmaceuticals sector, despite the company's negative net income and low franchise/durability score. The market may be assigning value to the potential for new drug pipeline catalysts, which is not in the model. The biggest risk to our model's base assumptions proving too high is that the company's operating cash flow, currently $1.9 million, declines rather than growing at the modeled rate.
As of today
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What's free cash flow / what do these mean?
Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.
Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.
Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.
Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
- Improvement in net income to positive territory
- Sustained growth in operating cash flow
- Successful advancement of drug pipeline through clinical trials
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Revenue fell -35% to $16.6M.
- Free cash flow fell to $1.8M.
- Gross margin shrank to 21% (-28 pts).
- Swung to a loss of -$10.0M (from a profit the prior year).
Nothing was clearly improving year-over-year.
Management & Leadership
Songlin Song and Aiden Han serve as Co-Chief Executive Officers, with Ping (Nmn) Wang as Chief Financial Officer. Other key executives include Yuhong (Nmn) Cheng, Vice General Manager, and Zhongyao Liu, Chief Operating Officer.
Co-Chief Executive Officer
Co-Chief Executive Officer
Chief Financial Officer
Chief Operating Officer
What They Make
Zhengye Biotechnology Holding Ltd operates in the pharmaceuticals industry, developing and selling biotechnology products. The company's paying customers are likely healthcare providers, distributors, and potentially direct consumers, depending on its product distribution model.
End Markets
Why Is It Priced Like This?
Why Customers Pay
ZYBT trades at a premium of +373.3% to the model's intrinsic valueIntrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation →. The market is pricing in significant future growth, with an implied growth rate of 37.2%, despite the company reporting negative net income in its latest fiscal year and having a franchise/durability score of 0/5. The market may be assigning value to the potential for regulatory wins for new drug approvals, which is not in the model.
Three Scenarios, Weighted
| Scenario | IV | Upside from today's price | Weight |
|---|---|---|---|
| Conservative | $0.31 | -81.8% | 40% |
| Base | $0.37 | -78.4% | 35% |
| Optimistic | $0.43 | -74.9% | 25% |
| Weighted | $0.37 | -78.9% | 100% |
Reading the last column: it is the move from today's price to each value (IV ÷ price − 1). The headline "premium/discount to model IV" measures the same gap from the value's side (price ÷ IV − 1), so the two percentages differ in size and sign by construction — e.g. a price 8% above value is a value 7.4% below price.
Business Model & Valuation
How They Make Money
The company's long-term debt is rising from $0M to $1M. With negative net income, it likely funds operations through a combination of existing cash and potential equity raises.
Free Cash Flow DCF Low
Owner-earnings FCF DCF: positive free cash flow (operating cash flow − capex − stock-based comp) in a sector suited for cash-flow-based valuation. High P/FCF (70x) - market pricing significant growth.
▾ Why is DCF applicability "Low" for ZYBT?
- Declining recent results (revenue declining), which a backward-looking model struggles to price.
- Individual business-segment drivers are not forecast separately — the model works off consolidated cash flow only.
Because of this, we headline the more conservative discount rate and urge you to weight the reverse-DCF, leverage, and operating trends alongside the DCF.
Show advanced inputs
| Revenue Growth | -34.8% |
| Historical Fcf Growth | -53.0% |
| Sector Default | 10.0% |
| Sector Default Source | Healthcare sector default |
| Best Estimate | 10.0% |
| Method | sector_default |
| Growth Basis | total |
What this model does NOT do: this is a consolidated owner-earnings cash-flow model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
The company reported declining net income in the latest fiscal year, with revenue at $16.6 million.
Geography & Markets
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)63.7NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
What's been happening
Zhengye Biotechnology Holding Ltd (ZYBT) operates in the biotechnology sector, primarily focusing on research, development, manufacturing, and sales of biological products. Over the past six months, there have been no significant publicly reported operational changes, new product launches, or major regulatory actions directly impacting the company's core business model. The company's revenue and margin trends have not been widely discussed in recent public disclosures, suggesting a period of relative stability or limited new developments. There have been no prominent legal cases or segment shifts reported that would materially alter its current business trajectory.
- lack of recent material news
- limited public information
News summary written by Gemini gemini-2.5-flash, refreshed Sep 10, 2026. AI can be wrong; verify before acting.
QUALITY
Data Quality & Risk Flags (5 notes — click to expand/collapse)
Guardrail Notes (3)
- Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
- Illiquidity discount 15% applied (small/micro-cap — harder to exit, demand a margin).
- Extreme valuation gap (P/IV 4.73): result may be dominated by model assumptions, share count issues, or sector-specific dynamics. Treat as low confidence.
FINANCIALS
Financial Statements (5-year tables — click to expand)
From Zhengye Biotechnology Holding Ltd's SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | 16.6M | -10.0M | $-0.21 |
| 2024 | 25.5M | 1.6M | $0.03 |
| 2023 | — | — | $0.00 |
| 2022 | — | — | $0.00 |
Cash Flow (5yr)
| Year | Operating CF | CapEx | − SBC | Free Cash Flow |
|---|---|---|---|---|
| 2025 | 1.9M | 144,000 | — | 1.8M |
| 2024 | 5.6M | 1.9M | — | 3.8M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). This is the same owner-earnings FCF definition the valuation model uses.
Balance Sheet
| Total Assets | 62.4M |
| Total Liabilities | 18.6M |
| Equity | 35.7M |
| Total Debt | 1.4M |
Recent video coverage
Top recent YouTube videos by date. We don't endorse the channels — these are surfaced for context.
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.
The questions people ask about ZYBT
Is Zhengye Biotechnology Holding Ltd (ZYBT) a good stock to buy?
Zhengye Biotechnology Holding Ltd (ZYBT) looks expensive against its own cash flows: the price is about 373% above our $0.37 estimate. Whether it is a good buy depends on whether the company can grow faster than that price assumes, on its financial health, and on what insiders are doing. All three are on this page. This is educational research from SEC filings, not investment advice.
Is Zhengye Biotechnology Holding Ltd (ZYBT) overvalued?
Yes, by our measure. Zhengye Biotechnology Holding Ltd (ZYBT) trades at $1.73, about 373% above our estimate of $0.37 for what the business is worth. This is educational research from SEC filings, not investment advice.
What is ZYBT's intrinsic value?
Our model estimates ZYBT is worth about $0.37 per share, built from the cash the business is expected to generate, taken from its SEC filings. The market price is $1.73.
What growth is priced into ZYBT?
Working backwards from today's price, the market expects ZYBT's cash flow per share to grow by roughly 37.2% a year over the next five years. Compare that with the company's actual record on this page.
Where do these numbers come from?
From Zhengye Biotechnology Holding Ltd's own SEC filings (10-K and 10-Q), Form 4 insider filings and daily market prices. Every figure on the page links to how it was calculated, and the model's weak spots are listed next to its results.